Suzanne Coberly
Amgen
10 Papers
99 Citations
Suzanne Coberly is an academic researcher from Amgen. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 7, co-authored 10 publications.
Chat about Author
Papers
The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo
Deryk Loo,Nancy Pryer,Peter R. Young,Tony W. Liang,Suzanne Coberly,Kathleen King,Key Kang,Penny Roberts,Mary Tsao,Xiaolin Xu,Beverly Potts,Jennie P. Mather +11 more
TL;DR: Preclinical data has led to the initiation of a phase I/IIA clinical study of RAV 12 in patients with metastatic or recurrent adenocarcinoma, and RAV12 inhibited the growth of RAAG12-expressing gastrointestinal tumor xenografts in athymic mice.
69
Fibroblast Growth Factor Receptor 4 (FGFR4) Deficiency Improves Insulin Resistance and Glucose Metabolism under Diet-induced Obesity Conditions
Hongfei Ge,Jun Zhang,Yan Gong,Jamila Gupte,Jay Ye,Jennifer Weiszmann,Kim Samayoa,Suzanne Coberly,Jonitha Gardner,Huilan Wang,Tim Corbin,Danny Chui,Helene Baribault,Yang Li +13 more
TL;DR: It is shown thatFGFR4 deficiency in mice leads to improvement in glucose metabolism, insulin sensitivity, and reduction in body weight under high fat conditions, and the results described herein suggest that FGFR4 antagonists alone, or in combination with other agents, could serve as a novel treatment for diabetes.
64
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen S. Keegan,Cong Li,Zhihong Li,Ji Ma,Mark L. Ragains,Suzanne Coberly,David Hollenback,John Eksterowicz,Lingming Liang,Margaret F. Weidner,Justin N. Huard,Xianghong Wang,Grace Alba,Jessica Orf,Mei-Chu Lo,Sharon Zhao,Rachel Ngo,Ada Chen,Lily Liu,Timothy J. Carlson,Christophe Queva,Lawrence R. McGee,Julio C. Medina,Alexander Kamb,Dineli Wickramasinghe,Kang Dai +25 more
TL;DR: Preclinical evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor, which combines inhibition of two kinases essential for proliferation and survival ofFLT3-mutated AML cells, may improve and prolong clinical responses.
38
Soluble CLEC2 Extracellular Domain Improves Glucose and Lipid Homeostasis by Regulating Liver Kupffer Cell Polarization
Xinle Wu,Jun Zhang,Hongfei Ge,Jamila Gupte,Helene Baribault,Ki Jeong Lee,Bryan Lemon,Suzanne Coberly,Yan Gong,Zheng Pan,Ingrid C. Rulifson,Jonitha Gardner,William G. Richards,Yang Li +13 more
TL;DR: The soluble form of the extracellular domain (ECD) of C-type lectin-like receptor 2, CLEC2, regulates Kupffer cell polarization in the liver and improves glucose and lipid parameters in diabetic animal models, revealing a previously unidentified role forCLEC2 as a regulator of macrophage polarity.
10
•Journal Article
The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines, modulates angiogenic factor secretion, and exhibits potent anti-tumor activity in vivo
Claudia B. Fieger,Francine Chen,Suzanne Coberly,Mark Armanini,Y Chen,Jeff Hooley,Monica Licea,Jonathan Yu-Meng Li,Panjing Li,Tony W. Liang,Beverly Potts,Peter Young,Jennie P. Mather +12 more
TL;DR: This is the first report of regulation of angiogenic factors by tumor stem cells with an antibody that is aware of, and suggests that regulation of VEGF may contribute to the anti-tumor activity of TES7 observed in vivo.
9